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Tumor metastasis into the central nervous system (CNS) and lymph nodes (LNs) is
a major obstacle for effective therapies. Therapeutic monoclonal antibodies (mAb)
have revolutionized tumor treatment; however, their efficacy for treating metastatic
tumors-particularly, CNS and LN metastases-is poor due to inefficient penetration into
the CNS and LNs following intravenous injection. We recently reported an effective
delivery of mAb to the CNS by encapsulating the anti-CD20 mAb rituximab (RTX)
within a thin shell of polymer that contains the analogs of choline and acetylcholine
receptors. This encapsulated RTX, denoted as n-RTX, eliminated lymphoma cells
systemically in a xenografted humanized mouse model using an immunodeficient mouse
as a recipient of human hematopoietic stem/progenitor cells and fetal thymus more
effectively than native RTX; importantly, n-RTX showed notable anti-tumor effect on
CNS metastases which is unable to show by native RTX. As an important step toward
future clinical translation of this technology, we further analyzed the properties of n-
RTX in immunocompetent animals, rats, and non-human primates (NHPs). Our results
show that a single intravenous injection of n-RTX resulted in 10-fold greater levels in
the CNS and 2-3-fold greater levels in the LNs of RTX, respectively, than the injection
of native RTX in both rats and NHPs. In addition, we demonstrate the enhanced
delivery and efficient B-cell depletion in lymphoid organs of NHPs with n-RTX. Moreover,
detailed hematological analysis and liver enzyme activity tests indicate n-RTX treatment
is safe in NHPs. As this nanocapsule platform can be universally applied to other
therapeutic mAbs, it holds great promise for extending mAb therapy to poorly accessible
body compartments.
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INTRODUCTION
Therapeutic monoclonal antibodies (mAbs) such as rituximab
(RTX, anti-CD20 for B-cell lymphomas) and trastuzumab (anti-
HER2 for breast cancer) have revolutionized treatment for
various types of cancers. However, their benefit in treating
metastasized tumors of the central nervous system (CNS) or
through lymphatic vessels into lymph nodes (LNs) (1, 2),
is transient and limited, increasing life expectancy by only
a few months. A major mechanism that renders metastasis
more resistant to mAb treatment than primary tumors is
limited antibody delivery into the CNS and lymphatic vessels
(3, 4). Intraventricular or intrathecal administration of mAbs
allows for bypass of the blood-brain barrier (BBB), resulting
in relative effectiveness of antibody therapy in treating brain
tumor metastases (5, 6); however, neurotoxicity and rapid
efflux are known to hinder mAb application for brain tumor
treatment (7). Subcutaneous administration of mAb targeting
metastatic tumors shows the advantages of entering lymphatic
vessels and binding to metastases in lymph nodes (LNs) (8).
However, the restriction to regional nodes, toxicity at injection
sites, and limited reach to organs without lymphatic vessels
are major obstacles to using subcutaneous administration of
mAb in treating systemic metastases (9). Therefore, a systemic
intravenous injection route is the ideal means for administration
of mAb treatment against metastatic tumors.
To improve BBB penetration for mAb delivery to the brain,
modifications with various chemicals or biological components,
such as lipidation or molecular targeting ligands, have been
attempted (10, 11). Another strategy uses colloidal carriers
such as liposomes, micelles, and nanoparticles, which transport
cargos across the BBB by endocytosis and/or transcytosis (12–
14). Improved therapeutic efficacy of these approaches has been
demonstrated in rodents with brain tumors, Alzheimer’s disease,
acute ischemic stroke, and Parkinson’s disease (15–17); however,
non-specific tissue accumulation—including in liver, spleen, and
kidney—is known to mediate acute toxicity and further decrease
the effective amount of mAbs in the CNS (18). Moreover, none
of those approaches achieved improvement of both LN and brain
delivery at the same time.
Our nanotechnology platform utilizes “nanocapsules”
which form a thin polymer shell that encapsulates individual
macromolecules, protein, RNA, or DNA inside and protects
them from the physiological environment (19–27). The
shell is formed by in situ polymerization of monomers
and stabilized by environmentally-responsive crosslinkers;
cargoes can be released only through cleavage of these
crosslinkers. We tailored these nanocapsules for CNS
delivery with zwitterionic properties imbued by polymer
shells composed of 2-methacryloyloxyethyl phosphorylcholine
(MPC), which is clinically approved for use in coatings on
implanted medical devices. MPC renders the polymer shells
of nanocapsules highly biocompatible and efficacious due
to low protein adsorption, improved circulation times, and
minimal immunogenicity (28, 29). Moreover, such nanocapsules
can effectively penetrate the BBB and deliver encapsulated
macromolecules to the CNS via nicotinic acetylcholine receptors
and choline transporters (30). This technology has demonstrated
efficacy for neural regeneration in mice with spinal cord injuries
(31) and antibody therapies for primary brain tumors (32)
in mice.
Rituximab (RTX), a chimeric anti-CD20 monoclonal
antibody, is used for treatment of B-cell malignancies such
as non-Hodgkin’s lymphomas (NHL) as well as chronic
lymphocytic leukemia (CLL) (33). RTX administration
contributes significant advancements toward systemic
CD20+NHL control, but treatment of primary and relapsed
CNS lymphomas is inefficient due to poor penetration through
the BBB (4). We recently demonstrated clearance of human
B-cell tumors with brain metastases in xenograft humanized
NOD-SCID-IL2receptor γnull (NSG) mouse models by RTX
nanocapsules (n-RTX) (34). Though these results are promising,
further studies are limited by the challenge in collecting
successive samples of cerebrospinal fluid (CSF) from the same
mouse for analysis; moreover, the delivery into LNs, which are
highly atrophic, cannot be confirmed in NSG mice. To address
these limitations, we designed studies of n-RTX in both rats
and non-human primates (NHPs) to further investigate delivery
and biodistribution in both lymphatic tissues and CNS, and
B-cell ablation in NHPs. Following a single IV dose of n-RTX,
encapsulated RTX is released and maintained in blood for weeks
resulting in effective B-cell ablation in blood and lymphatic
tissues of NHPs. Importantly, we show significantly improved
RTX delivery to the CNS and lymph nodes with no notable
adverse effects.
RESULTS
Formulation of Nanocapsules With
Hydrolysable Crosslinkers to Release
mAbs
A formulation of nanocapsules with timed-release capabilities
in vivo was synthesized based on previously published
nanocapsules (19). We screened and selected two crosslinkers to
sustain release at physiological conditions in vivo: hydrolysable
crosslinker—poly (lactide-co-glycolide)-b-poly(ethylene
glycol)-b-poly(lactide-co-glycolide) (PLA-PEG-PLA) and non-
hydrolysable crosslinker—glycerol dimethacrylate (GDMA),
which degrade rapidly and slowly, respectively, at physiological
pH conditions. The ratios between and GDMA impact the release
kinetics. With a higher PLA-PEG-PLA ratio, the crosslinkers
will degrade in a shorter time. As the crosslinkers degrade,
the shells of nanocapsules will loosen, swell, and dissociate
resulting in the release of encapsulated mAbs. As shown in
Figure 1A, nanocapsules encapsulating mAbs are synthesized
through the following processes: first, the zwitterionic monomer
(MPC) and two crosslinkers, PLA-PEG-PLA and GDMA, are
enriched around the surface of the mAb (in this case, RTX)
through hydrogen bonding (Step 1). Subsequent polymerization
in an aqueous solution at 4◦C wraps each molecule with a thin
shell of polymer through in situ free-radical polymerization
(Step 2). Finally, crosslinkers stabilize the polymer structure
and release mAbs upon hydrolysis (Step 3). Transmission
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FIGURE 1 | Developing timed-release nanocapsules of RTX. (A) Scheme of the synthesis of and release by timed-release RTX nanocapsules (n-RTX) by (1) enriching
zwitterionic monomer (MPC), hydrolysable crosslinker 1 (PLA-PEG-PLA) and non-hydrolysable crosslinker 2 (GDMA) around a RTX molecule, (2) in-situ polymerization
of the monomer and crosslinkers forming a thin shell of polymer around an RTX molecule, and (3) releasing RTX when polymer shells are degraded under
physiological condition. (B) Transmission Electron Microscopy image of n-RTX. (C) Size distribution of n-RTX measured by dynamic light scattering measurement.
(D) Nanocapsules with mixed hydrolysable crosslinkers achieve timed release of RTX in rhesus macaque plasma. The nanocapsules synthesized with mixed
PLA-PEG-PLA and GDMA crosslinkers at different ratios. Release kinetics of n-RTX with 100, 50, 30, 10, and 0% of PLA-PEG-PLA were tested. Thirty micrograms of
nanocapsules were incubated in 1mL of rhesus macaque plasma at 37◦C. The concentration of released RTX was determined by ELISA.
electron microscopy (TEM) and dynamic light scattering
(DLS) measurements show that these nanocapsules form a
spherical morphology of 20–30 nm encasing mAb molecules
inside (Figures 1B,C). Dependent on the ratios between
PLA-PEG-PLA and GDMA, nanocapsules release RTX at
different rates when incubated in rhesus macaque plasma in
vitro (Figure 1D). The RTX concentration was detected by
enzyme-linked immunosorbent assay (ELISA) using anti-RTX
(anti-idiotype) antibody, which can only detect the free RTX
released from nanocapsules since nanocapsules shields the
epitopes of encapsulated antibodies by the polymer shells.
The n-RTX with 50 and 30% PLA-PEG-PLA crosslinkers
showed an intermediate level of release over 6 days. We already
demonstrated improved CNS delivery of n-RTX with 50% PLA
nanocapsules in mice in our published work (35), so the same
formulation for following in vivo studies in rats and NHPs
was used. We also demonstrated that improvement of CNS
delivery with this nanocapsules formulation is applicable to
other therapeutic mAbs. To prove this point, we tested Herceptin
(anti-Her2) for breast cancer; similarly to n-RTX, Herceptin
nanocapsules (n-Hercepin) show increased delivery to the
CNS (Figure S1).
Improved Delivery to CNS and LNs of Rats
by RTX Nanocapsules
We demonstrated the improved delivery to CNS and LNs
by n-RTX using rats where greater amounts of CSF facilitate
serial sampling within the same animals and mature LN
formation enables clear visualization and detection in the
lymphatic system. Native RTX and n-RTX, normalized with
of the same amount of RTX for a single IV dose, showed
comparable RTX level in plasma (Figure 2A). Whereas, native
RTX in CSF was <0.1% of plasma levels, RTX released
from n-RTX was 1%, and was maintained this level to
days 14 and 21 when native antibody was barely detectable
at day 4 (Figure 2B). At the endpoint, RTX levels in
brain tissue were consistent with the CSF results; higher
levels of RTX were observed in the n-RTX treated animals
(Figure 2C). These results provide proof of concept for improved
antibody delivery in the CNS compared to the native form.
Improved levels of RTX from n-RTX are also observed
in lymphatic-tissues, which include organs such as spleen,
LNs in different locations, and three sections of the small
intestine (Figure 2C). Tissue imaging shows clear biodistribution
of fluorescently labeled native RTX and n-RTX on day 1
post-injection (Figure 2D). Compared to native RTX, n-RTX
shows an improved distribution in lymphatic-tissues containing
organs including LNs and spleen and, importantly, reduced
accumulation in lung, liver, and kidney—major organs involved
with clearance of recombinant antibodies. The decreased
accumulation in lung, liver, and kidney is due to the superior
anti-fouling property of n-RTX, which decrease the uptake by
immune surveillance cells. The difference in biodistribution
between RTX and n-RTX is further confirmed by quantifying
the relative fluorescence units of the fluorescence label from each
organ (Figure 2E).
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FIGURE 2 | Nanocapsulation of RTX improves levels of its tissue penetration, including CNS, in rats. A single dose (5 mg/kg) of native RTX or n-RTX was
administered in rats through IV (intravenous) injection (n = 3). (A–C) The concentrations of free RTX in plasma (A) on Days 1, 2, 3, 4, 5, 6, 7, 14, and 21 and CSF
(B) on Days 1, 4, 7, 14, and 21 were determined by ELISA. (C) Tissues, including LNs at three different locations, jejunum, ileum, colon, spleen, liver, and brain, were
harvest at necropsy after perfusion on Day 22. Tissues were homogenized in PBS (1mg tissue in 100 µl PBS), and tested by ELISA for RTX concentrations. A higher
single dose (15 mg/kg) of fluorescent labeled native RTX or n-RTX was administered in rats through IV injection (n = 1) and monitored on IVIS in vivo imaging (D,E).
Organs were isolated and monitored by IVIS imaging on Day7 after injection. (E) Signal intensity from free RTX in each organ was quantified by software Living Image.
Data were generated from n = 3 rats. Data are shown as means ± s.d. of biological triplicate. Statistical significance between native and nanocapsules was
determined by one-tailed Mann–Whitney–Wilcoxon test. *Significant, p < 0.1; ns, not significant.
Enhanced Delivery of RTX Nanocapsules
to the Brain of Rhesus Macaques
As an essential step toward future clinical translation of
nanocapsules, we further analyzed the properties of n-RTX in
non-human primates (NHPs). The study design is summarized
in Figure 3. Four rhesus macaques were intravenously infused
with a single dose (5 mg/kg, normalized for the RTX amount)
of native RTX or n-RTX and processed for necropsy on Day
21 (Group I, #12025 and #13029) or Day 63 (Group II, #12069
and 12019). Blood samples were collected on Days 1, 3, 5,
and 7 in the first week, and every 7 days after that (Figure 3,
Stars). CSF sample collection started before infusion as a baseline
(Figure 3, Day-12), on Day 3 post-infusion, and continued every
7 days until Day 21 for Group I; for Group II, CSF collection
was initiated on Day 1 post-infusion and continued every week
until Day 63. Lymph node (LN) biopsies were performed on
Days 3 and 14 in Group I and on Days 3, 17, 28, and 42 in
Group II (Figure 3, Double triangles). Eight tissues, including
brain, thymus, lung, liver, spleen, kidney, intestine, and LNs, were
harvested at necropsy following perfusion. LNs from different
locations (inguinal LN, axillary LN, and mesenteric LN), and
three pieces (3 × 3 cm) from each of other tissues were collected
and used for ELISA assays. Brain and LN samples were also used
for immunohistochemical (IHC) analysis.
We successfully demonstrated the enhanced CNS delivery of
n-RTX in rhesus macaques (Figure 4). The levels of RTX released
from n-RTX in rhesus macaque plasma was slightly lower on Day
1 compared to that of native RTX, probably due to the controlled
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FIGURE 3 | Experimental schedule of RTX brain delivery in non-human primates. Four rhesus macaques were administered with a single 5 mg/kg dose of native RTX
(Monkey ID #12025 and #12069) and n-RTX (Monkey ID #13029 and 12019) via IV infusion. Peripheral blood, CSF, and Inguinal lymph nodes were collected as
scheduled. Other tissues were harvested at necropsy on Days 21 or 63 after perfusion.
RTX release from n-RTX in plasma (Figure 4A). The plasma
level remained stable for 1 week, followed by a gradual decreased
over time. Two animals treated with n-RTX (#13029 and 12019)
showed 5- and 2.5-fold greater levels of free RTX in the CSF
compared to those in native RTX-treated animals (#12025 and
12069), respectively, within the first week (Figure 4B). Native
RTX fell below detection limits by Day 14, whereas free RTX
released from n-RTX persisted until Day 21 in both groups. RTX
concentration in the tissue homogenates was also assessed by
ELISA (Figure 4C). In Group I, the animal treated with n-RTX
(#13029) showed significantly higher levels of RTX in all tissues
than that treated with native RTX (#12025) in all tissues. A similar
trend was confirmed with animals in Group II, but the difference
between those two treatments was less significant. Five regions
of the brain, including the frontal, parietal, temporal occipital
lobes, as well as cerebellum, were homogenized separately for
ELISA. RTX was only detectable in Group I. RTX released from
n-RTX was observed at approximately 4-fold levels in all brain
regions than that in the brain tissues from the RTX-treated
animal (Figure 4D).
Liver toxicity is a major concern for use of nanomedicines
in vivo (35). Thus, liver damage is the one of the indexes of
nanomedicine safety. In order to show that this nanocapsule
platform improves brain delivery efficiency of therapeutic
antibodies through systemic injection without inducing liver
toxicity, three liver enzymes indicating acute liver toxicity
were closely measured over the course of experiments: alanine
aminotransferase (ALT), aspartate aminotransferase (AST), and
alkaline phosphatase (ALP) (Figure 5A). As we confirmed in
mice previously (34), no notable differences exist in levels
between animals treated with RTX or n-RTX. Neither a
complete liver function assay including serum globulin (GLB),
indirect bilirubin (IBIL), gamma-glutamyl transferase (γ-GT),
total protein (TP), and albumin (ALB), nor a blood chemistry test
for white blood cell (WBC) count, lymphocyte count, monocyte
count, neutrophil count, hemoglobin (HGB), hematocrit (HCT),
and platelet counts (PLT), showed major differences between
those animals (Figure S2). We have hereby concluded that n-
RTX increases antibody delivery into the CNS by 4–10-fold with
no detectable level of acute systemic toxicity.
We further showed no potential neurotoxicity caused by n-
RTX treatment. Two well-known neurotoxicity markers were
used in this test: glial fibrillary acidic protein (GFAP), of which
levels increase with reactive gliosis (36), and ionized calcium-
binding adapter molecule (IBA-1), of which levels increase upon
mediating neuroinflammation (37). Compared to native RTX-
treated animals, brain tissues of n-RTX treated animals showed
normal morphology and no elevated expressions of those two
markers (Figures 5B,C).
Comparison of Effector Activity Mediated
by Native RTX and n-RTX
Lastly, we observed comparable B cell depletion by RTX and n-
RTX in peripheral blood of NHPs. CD20 can be internalized by
the binding of RTX (38, 39), so single staining for cell surface
CD20 may underestimate total B cell levels. To more accurately
measure B cell levels, we stained cells with both CD19 and CD20
antibodies. To minimize CD20 epitope masking by RTX, we
used the CD20 antibody clone L26, which recognizes different
epitope on rhesus CD20 molecules not blocked by RTX (40).
Analysis by single staining for CD19+ showed similar results
to double staining for CD19+/CD20+ cells (data not shown).
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FIGURE 4 | Nanocapsulation of RTX improves levels of its tissue penetration in non-human primates. A single dose (5 mg/kg) of native RTX or n-RTX was
administered in rhesus macaques through IV infusion (A,B). The concentrations of free RTX in plasma (A) and CSF (B) were determined by ELISA. (C) At the endpoint
of Group I (Day 21) and Group II (Day 63), LNs at three different locations, jejunum, ileum, colon, thymus, lung, spleen, liver, kidney, and brain were harvest after
perfusion. Whole LNs and three pieces (3 × 3 cm) of other tissues were homogenized in PBS (1mg tissue in 100 µl PBS) for ELISA test. (D) Five different regions of
the brain (frontal, parietal, temporal occipital lobes, and cerebellum) were homogenized in PBS (1mg tissue in 100 µl PBS) for ELISA test. Data are shown as means ±
s.d. of biological triplicate. Statistical significance between native and nanocapsules was determined by one-tailed Mann–Whitney–Wilcoxon test. *Significant, p < 0.1,
ns, not significant.
CD19+/CD20+ B cell levels dropped ∼80–90% within the first
7 days after treatment by both RTX and n-RTX (Figure 6A).
Aside from the expected drop in B cells, the numbers of total
WBCs, neutrophils, lymphocytes, and monocytes were relatively
stable (Figure S3), indicating B-cell specific depletion by RTX in
both forms. Levels of total CD3+ cells, CD3+/CD4+ T cells, and
CD3+/CD8+T cells were also stable over the course of treatment
(Figures 6B–D).
To assess the specificity of depletion and accessibility to B
cells in lymphoid tissues, we analyzed levels of B-cell depletion
in LNs at three different localities: axillary, mesenteric and
inguinal, by IHC analysis. Antibodies for CD20+, CD3+, and
Bcl-6 were included to distinguish three different types of cells,
B cells, T cells, and T follicular helper cells (Figure 7A). By
further quantitative analysis of IHC staining results, CD20+
B cells showed a lower density in all three LNs of animals
treated with n-RTX compared to that of native RTX on Day 21
(Figure 7B). Ratios of B cell against T cell (B/T ratio) detected
by flow cytometry in inguinal LN indicated that n-RTXmediated
prolonged B cell depletion over the course of treatment compared
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FIGURE 5 | RTX nanocapsules do not mediate notable levels of acute toxicity in the liver and brain. (A) Rhesus macaques were administrated with a single dose (5
mg/kg) of native RTX or n-RTX. Plasma samples were collected as scheduled and served for measuring levels of aspartate transaminase (AST), alanine transaminase
(ALT), and alkaline phosphatase (ALP) by ELISA. (B) Brain tissues obtained from five different parts were fixed by 4% paraformaldehyde and processed for IHC
analysis. Representative images of immunohistochemical staining for GFAP (astrocyte marker) and IBA-1 (microglial marker) were shown. Scale bar = 100µm. (C) A
positive pixel count in images (4 mm2 ) from five different brain parts was quantified using Aperio ScanScope slide scanner. Positive pixel calculation for GFAP used the
following variables: hue width = 0.371 and color saturation threshold = 9.7e-002. Positive pixel calculation for IBA-1 used the following variables: hue width = 0.5 and
color saturation threshold = 4.0e-007. % positivity was calculated by total number of positive pixels divided by the total number of pixels. Data are shown as means ±
s.d. of biological triplicate. Statistical significance, compared with the native RTX group, was determined by one-tailed t-test with Welch’s correction. ns, not significant.
to native RTX (Figure S4). In contrast, no significant difference
in levels of CD3+ T cells was confirmed between LNs treated
with native RTX or n-RTX. The level of Bcl-6 expression in LNs,
a marker of germinal center B cells and T follicular helper cells,
showed no difference between two animals.
DISCUSSION
We utilized a platform wherein single mAbs are encapsulated
within a thin polymer shell, called a “nanocapsule,” to improve
delivery of anti-tumor antibodies to the brain. Formulations were
modified to utilize neutral polymers with zwitterionic properties
(MPC polymers) and crosslinkers that hold the shell together
which are later gradually hydrolyzed for timed release of mAb
in a suitable microenvironment. This successful nanocapsule
design sustains RTX in circulation, allows penetration into the
brain, reaches deep tissues including LNs, and releases RTX
in a controlled fashion. Our results detail the first test of
a zwitterionic nanocarrier—nanocapsule—for therapeutic mAb
delivery in NHPs. Importantly, the data clearly show efficient and
prolonged delivery of RTX into both the CNS and LNs by a single
dose of intravenous injection with no notable acute liver toxicity
nor neurotoxicities.
Therapeutic mAbs are effective for treating several tumors;
however, their performance is limited in the treatment of
metastases in CNS and LNs, where the physical barriers are
considered as one of themajor obstacles to achieve effectivemAbs
delivery. Although subcutaneous administration is considered
as an effective route for LN delivery through the absorption by
lymphatic capillaries, the delivery into the lymphatic system is
delayed due to the limitation of the absorption rate (41, 42).
Moreover, the brain delivery of mAbs through subcutaneous
administration is challenging due to the low concentration
of mAbs in plasma. Therefore, intravenous injection is still
a commonly used administration route for mAb therapy.
However, achieving a high plasma concentration is insufficient
for treatment of brain cancers due to poor delivery through
the BBB. While multiple strategies have been attempted to
facilitate greater antibody penetration through the BBB, the
potential risks outweigh most benefits. One approach is to
disrupt the tight junctions, allowing for passage, however, this
approach raises safety concerns for the brain environment
(43). Other approaches are the modification and engineering
of mAbs to improve brain delivery; attaching charged or
lipophilic moieties to mAbs to enhance absorptive-mediated
transport, but those modifications are known to result in
unexpected biodistribution, low sustainability, and insufficient
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FIGURE 6 | Both native and nanocapsulated RTXs mediate similar levels of peripheral blood B cell depletion in rhesus macaques. Whole blood was collected as
scheduled and processed for monitoring immunophenotyping by flow cytometry. (A) CD19+CD20+ B cells, (B) CD3+ total T cells, (C) CD4+T cells, and (D) CD8+T
cells. (A,B) CD19+CD20 B cells and CD3+ T cells were showed by absolute numbers per 1mL of blood. (C,D) The percentages of CD4+ T cells and CD8+ T cells
in CD3+ T cells were normalized over baseline.
efficacy (44, 45). mAbs have also been encapsulated or conjugated
with nanoparticles or liposomes to induce receptor-mediated
transcytosis on the BBB (46, 47), but the efficacy, safety, and
stability in NHPs are still unknown. Thus, despite decades of
effort, effective delivery of mAbs to the both LNs and the CNS
remains challenging.
We used the nanocapsule platform to achieve systemic
delivery of RTX into both the CNS and LNs in both rodents
and NHPs with single intravenous injection. The choline and
acetylcholine analogous structures on the MPC polymer chains
of nanocapsules, which can induce transcytosis through the BBB
via nicotinic acetylcholine receptors and choline transporters,
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FIGURE 7 | Nanocapsulated RTX mediates superior B-cell depletion in LNs of rhesus macaques. LNs from three different locations (inguinal, axillary, and mesenteric)
were collected at necropsy on Day 21 from Group I rhesus macaques with a single dose (5 mg/kg) of native RTX or n-RTX via IV and processed for
immunohistochemical (IHC) analyses. (A) H&E (top) and IHC staining of CD20 (B cell, second), CD3 (T cell, third), and Bcl-6 (Germinal center, bottom) were performed
on serial sections. Panels from left to right show the expression level in axillary, mesentery, and inguinal LNs, respectively. Scale bar = 50µm. (B) 6.8 × 5 cm of each
CD20 and CD3 positive staining (n = 7), and 3.4 × 4.2 cm of Bcl-6 (n = 4) were randomly selected and gray pixel values were measured by Image J software. Each
bar indicates the mean inverse gray value ± standard deviation (mean ± SD). One-tailed t-test with Welch’s correction was used for the statistical analysis. **p < 0.01.
H&E, hematoxylin and eosin stain.
play an important role to accomplish CNS penetration (30).
In NHPs treated with nanoencapsulated RTX, levels of RTX in
the CSF were 100 to 300 ng/mL over 14 days, which are 4–10-
fold greater than that observed for native RTX in the CSF. It
indicates that our nanocapsule platform achieved higher brain
delivery compared to animals treated with native RTX.Moreover,
similar to animals treated with native RTX, those treated with
nanocapsules exhibited no notable blood, liver, or neuronal
toxicities. These studies were conducted in immune competent
rats and outbred NHP more closely modeling human therapy
than in our previous studies utilizing immunodeficient mice.
While these levels of RTX in the CNS were sufficient to clear
xenografted B cell lymphomas in the immunodeficient mice, it is
unclear whether these levels are high enough to have therapeutic
efficacy in humans. Our results on biodistribution and safety
profiles provide a rationale for further assessing efficacy and
safety in human clinical studies.
CONCLUSION
Our studies suggest a non-invasive facile solution suitable
for human application to address this critical issue of poor
anti-cancer mAb deliverance to both LNs and the CNS. To
date, similar results are obtained with one additional clinically
approved anti-cancer mAb, anti-Her2 (Herceptin), as well
as other non-therapeutic mAbs such as anti-CD4 (OKT4)
(unpublished data). The platform is highly versatile, with
biodistribution and pharmacokinetics being readily adjustable
by rational choice of chemical formulation of the polymer
shell. In addition to timed-release functionality via hydrolysis of
crosslinkers under physiological pH conditions, mAb release can
be further controlled by crosslinkers sensitive to environmental
factors such as endosomal low pH and proteases (21). Our study
supports the translation of therapy from animals to human
clinical studies. Further enhancements of the platform may
produce therapeutic delivery options for other diseases requiring
mAbs delivery into the CNS and/or LNs.
MATERIALS AND METHODS
Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO, USA) unless otherwise noted. All cell culture reagents
were purchased from ThermoFisher Scientific (Waltham, MA)
unless otherwise noted. Hydrolysable crosslinker Poly(DL-
lactide)-b-Poly(ethylene glycol)-b-Poly(DL-lactide)-diacrylate
triblock (PLA-PEG-PLA) was purchased from PolySciTech
Akina, Inc. (West Lafeyette, IN). Capture antibody for ELISA
against rituximab was purchased from Bio-Rad Laboratories
(HCA0620, Hercules, CA). Anti-CD19, anti-CD20, anti-CD3,
anti-CD4, and anti-CD8 for flow cytometry were purchased
from BioLegend, Inc (San Diego, CA, USA). Antibodies for
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IHC staining were purchased from different vendors, identifying
separately in Immunohistochemistry section. Rituximab,
RITUXAN (Genentech, Inc.) was purchased from the UCLA
hospital pharmacy.
Synthesis of Nanocapsules
The mAbs (RTX and Herceptin) were encapsulated via in-situ
polymerization technology. The mAb solution (2.2 mg/mL in
PBS) was mixed with MPC as monomer (40%m/v in PBS) and
AI102 (PLA-PEG-PLA, 10%m/v in PBS) as well as glycerol
dimethacrylate (GDMA, 10%m/v in DMSO) as degradable
crosslinkers. Then the polymerization was initiated by adding
ammonium persulfate (APS, 10% m/v in PBS) and N, N, N′,
N′-tetramethylethylenediamine (TEMED) solution. Synthesized
nanocapsules were dialyzed against PBS and purified by passing
through a hydrophobic interaction column (Phenyl-Sepharose
4BCL). Since the nanocapsules possess a super-hydrophilic
surface, their binding affinity to the column is much weaker
than the native mAb. Thus, encapsulated protein will be eluted
out with a high salt concentration buffer (10xPBS), whereas the
native mAb binds on the column. Purification is confirmed by
DLS and ELISA to show no free mAbs. Detailed parameters of
the synthesis are provided in the Table S1.
Transmission Electron Microscopy (TEM)
and Dynamic Light Scattering (DLS)
Measurements of the Nanocapsules
The nanocapsule solution (0.2mg/mL) 10µLwas dropped onto a
carbon–coated copper grid. After 45 s incubation, excess amount
of the samples was removed. The samples are stained with 1%
phosphotungstic acid (PTA) at pH 7.0 after being rinsed with
distilled water for three times. To investigate the size and zeta
potential of the nanocapsules, DLS measurements were taken
under the concentration of 0.5 mg/mL.
Pharmacokinetics and Bio-Distribution
Studies
Four male rhesus macaques were single administered with
5mg/kg of RTX and n-RTX via intravenous infusion in 30mL
sterile saline through femoral vein. 2–3mL peripheral blood was
collected in EDTA anticoagulant tubes and centrifuged at 5000
rpm/min for 2min, the plasma was separated and freeze down in
−80◦C for further purposes. 300–500µL CSF with no apparent
blood contamination continually collected through 3–4th lumbar
spine by 1mL syringe and frozen in −80◦C for ELISA test.
All animals were anesthetized with an intraperitoneal injection
of FFM mix (2.5mg Fluanisone, 0.105mg Fentanylcitrate, and
1.25mg Midozalam HCl/kg in distilled water). On Days 21 and
64 post-injection, animals were euthanized; tissues were removed
following heart perfusion with ice-cold saline and fixed in 4%
paraformaldehyde for further analyses.
Flow Cytometry
Five hundred microliters peripheral blood was used for staining
following the plasma separation. Cells was rinsed by cold PBS
(pH7.4) once, counted, and then suspended in FACS buffer (2%
FBS/PBS), followed by blocking with 2µL Human Trustain FcX
(BioLegend, US) at room temperature for 10min. Following
the staining of dead cells with LIVE/DEAD Fixable Violet
Dead cell staining kit, cells were incubated with PerCP-CY5.5-
conjugated mouse anti-human CD3, FITC-conjugated mouse
anti-human CD8, BV605-conjugated mouse anti-human CD4,
PE-conjugated mouse anti-human CD19, APC-CY7-conjugated
mouse anti-human CD20 in dark at 4◦C for 30min. Cells
were then rinsed with PBS for two times and fixed by 2%
paraformaldehyde in PBS. Expression levels were assessed by BD
LSRFortessaTM (BD Biosciences, Inc.), and analyzed with FlowJo
(FlowJo, LLC).
Preparation of Fluorescence Labeled RTX
Rhodamine-B-labeled RTX was prepared by following the
protocol provided by the manufacturer of fluorescence dyes.
Fluorescent dyes, Rhodamine-B (RhB), were first dissolved in
anhydrous DMSO to get 10 mg/mL stock solution, respectively.
Then 50µL of dye solutions were added gradually into
2mL enzyme solutions (10mg protein/mL, pH= 8.2, sodium
carbonate, 100mM). The reactions were carried out overnight at
4◦C. Labeled RTX were then dialyzed against phosphate buffer
(20mM, pH= 7), condensed by centrifugal filtration (MWCO
= 10 kDa) and stored at 4◦C for further use. The concentration
and dye/mAb ratio (D/P) were determined by the extinction
coefficients of 2,101,000M−1 cm−1 at 280 nm (RTX) and 108,000
M−1 cm−1 at 555 nm (RhB).
Tissue Imaging
The bioluminescence imaging of organs was performed with
IVIS Spectrum imager (PerkinElmer, Waltham, MA). Rats were
injected through IV with 15mg/kg of fluorescent labeled native
RTX or n-RTX and scarified at Day 7 post-injection. The tissue
images present the total photon flux per second within each organ
with rainbow color scales. To further quantifiably compare the
fluorescent intensity, and the fluorescent intensity from tissue
homogenates was quantified as Relative Fluorescence Unit (RFU)
per g.
Immunohistochemistry
Axillary, mesenteric, and inguinal lymph nodes, frontal, parietal,
temporal, occipital lobes, and cerebellum, were collected
separately and fixed in formaldehyde. Four micrometers
thickness section were cut serially post paraffin embedding.
For staining, slides were first heated at 60◦C for 1 h, then
deparaffinized in xylene twice and rehydrated in an ethanol
gradient. For antigen retrieval, LNs and brain lobes were
treated with citrate buffer (Vector Laboratories and Biocare
Medical, respectively) for 25min at 100◦C and for 50min
in pressure cooker post ddH2O rinse, respectively. Sections
were incubated with BLOXALL endogenous peroxidase (Vector
Laboratories) and alkaline phosphatase blocking solution (Vector
Laboratories) for 10min at room temperature, followed with
PBST (0.1% Tween-20) wash and serum blocking at room
temperature for 1 h. Primary mouse anti-human CD20 (1:200,
clone L26, Santa Cruz Biotechnology), which recognizes different
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epitopes on rhesus CD20 molecules not covered by RTX to
minimize CD20 epitope masking by rituximab, rabbit anti-
human CD3 (1:100, cloneSP7, Invitrogen), and mouse anti-
human Bcl-6 (1:100, cloneD8, Santa Cruz Biotechnology), were
incubated overnight at 4◦C, separately. Rabbit anti-human glia
fibrillary acidic protein (GFAP) (1:200, Biocare Medical), mouse
anti-human ionized calcium-binding adapter molecule 1 (IBA-
1) (1:100, clone 20A12.1, Millipore) were separately used to
identify astrocyte and microglia, respectively in brain lobes.
After rinsed in PBST, the slides were incubated with ImmPRESS
HRP universal secondary antibody at room temperature for
30min. Followed with PBST wash, 3,3′-diaminobenzidine (DAB)
staining, nucleus counterstaining, graded ethanol dehydration,
xylene clear, the sections were covered with mounting medium
(Thermo Fisher). Images were captured by inverted microscope
(DMi1, Leica), brown staining was considered as positive signal,
otherwise was considered as negative. Slides of lymph nodes were
analyzed with Image J (NIH); slides of brain lobes were scanned
by Aperio ScanScope slide scanner by 4× 4 grid (20×).
For analysis of lymph nodes, 6.8 × 5 cm of each 40 magnified
CD20 and CD3 positive staining (n= 7) and 3.4 × 4.2 cm
of Bcl6 (n = 4), was randomly selected and their optical
density (OD) numbers were calculated with the following
formula: OD = log (max intensity/Mean intensity), where
max intensity = 255 for 8-bit images. Brain slides were
performed with the Aperio Positive Pixel Count v9 algorithm.
Positive pixel calculation for GFAP used the following variables:
hue width = 0.371 and color saturation threshold = 9.7e-
002. Positive pixel calculation for IBA-1 used the following
variables: hue width = 0.5 and color saturation threshold =
4.0e-007. Positivity was calculated by total number of positive
pixels divided by the total number of pixels. The value was
then multiplied by 100 to give a percentage for positive
pixels. Total area analyzed for both GFAP and IBA is 4
mm2. One-way ANOVA from SPSS software (IBM) was used
for the analysis of statistical significance (∗∗P < 0.01), the
inversed gray value of positive stained tissue was showed in
histogram (mean± SD).
MAb Detection by Enzyme-Linked
Immunosorbent Assays (ELISA)
The concentration of RTX in animal body fluids and tissue
homogenates was measured by ELISA against RTX. RTX
levels were measured by ELISA using a monoclonal antibody
(HCA062, clone#AbD02844, Bio-Rad, Hercules, CA), which
specifically recognizes the idiotypic determinants of RTX.
The 96-well plates were coated with 1µg/mL of anti-RTX
antibody (diluted in sodium carbonate–bicarbonate buffer),
followed by blocking with 1% BSA/PBS for 2 h at room
temperature. Diluted samples of RTX in PBST from 0 to
500 ng/mL were then added and incubated for 1 h at room
temperature to obtain calibration curves. Animal body
fluids and tissue homogenates containing encapsulated
RTX in non-degradable nanocapsules were treated with
100mM sodium acetate buffer (pH 5.4) at 4◦C overnight
and used for ELISA measurement. Released RTX from
hydrolysable nanocapsules was directly measured with
animal body fluids and tissue homogenates. All animal
samples were added and incubated for an additional hour at
room temperature. After washing with PBST for five times,
peroxidase-conjugated anti-human Fc antibody was added and
incubated for a further hour at room temperature. The substrate
3,3′,5,5′-Tetramethylbenzidine (TMB) solution was added and
incubated until the appropriate color developed. The reaction
was stopped and absorbance at 450 nm was measured with a
plate reader (FLUOstar OPTIMA).
Animal Care and Ethics Statements
All research involving animals was conducted according to
relevant national and international guidelines. Male SD rats
(weighting 180–220 g, 6–8 weeks old) were provided by the
Experimental Animal Center of Medical Department of Peking
University. All interventions and animal care procedures
were performed in accordance with the Guidelines and
Policies for Anima l Surgery provided by our collaborator
institute (Chinese Academy of Medical Sciences & Peking
Union Medical College, Beijing, China) and were approved
by the Institutional Animal Use and Care Committee. The
rats were maintained in a temperature-controlled facility
(temperature: 22 ± 1◦C, humidity: 60%) with a 14 h light/10 h
dark photoperiod and free access to food and water. Male
rhesus macaques (weighing 4.8–5.2 kg, 4–5 years old) were
purchased from the Medical Primate Research Center of the
Institute of Medical Biology, Chinese Academy of Medical
Sciences, and housed and bred according to the guidelines.
The experimental protocols were reviewed and approved
by the Yunnan Province Experimental Animal Management
Association (SYXK-YN 2010-0009) and the Experimental
Animal Ethic Committee of the Institute, which complied
with the humane regulations of replacement, refinement,
and reduction.
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